Who is the new Executive Director at Nanoscope Therapeutics?

Nanoscope Therapeutics named Damon Daulerio Executive Director, announced November 5, 2026.

Where did Damon Daulerio work before joining Nanoscope Therapeutics?

Damon Daulerio joins from Insmed Incorporated.

Which similar companies made leadership changes around the same time?

Arcutis (November 5, 2026), Immuneering (November 9, 2026), OncoNano Medicine (November 10, 2026) and Harmony Biosciences (October 30, 2026) also announced leadership changes within 45 days of Nanoscope Therapeutics.

Nanoscope Therapeutics Appoints Damon Daulerio as Executive Director of Regulatory Affairs

PRIVATENov 05, 2026

New to company · from Insmed Incorporated“Most recently, he served as Senior Director, Regulatory Affairs (Rare Diseases) at Insmed Incorporated”

Position

Executive Director

Company

Nanoscope Therapeutics

Damon Daulerio

DallasBiotechnologyHealth CareMedicalTherapeutics

Description

Nanoscope Therapeutics Inc. announces the appointment of Damon Daulerio as Executive Director of Regulatory Affairs. Mr

Quick answer

Nanoscope Therapeutics Appoints Damon Daulerio as Executive Director of Regulatory Affairs (November 5, 2026). Nanoscope Therapeutics is based in Dallas, Texas, United States.

Who is the new Executive Director at Nanoscope Therapeutics?: Nanoscope Therapeutics named Damon Daulerio Executive Director, announced November 5, 2026.
What did Nanoscope Therapeutics announce on November 5, 2026?: Nanoscope Therapeutics Inc. announces the appointment of Damon Daulerio as Executive Director of Regulatory Affairs.
Where did Damon Daulerio work before joining Nanoscope Therapeutics?: Damon Daulerio joins from Insmed Incorporated.
What does Nanoscope Therapeutics do?: Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists.
Where is Nanoscope Therapeutics based?: Nanoscope Therapeutics is based in Dallas, Texas, United States.
Which similar companies made leadership changes around the same time?: Arcutis (November 5, 2026), Immuneering (November 9, 2026), OncoNano Medicine (November 10, 2026) and Harmony Biosciences (October 30, 2026) also announced leadership changes within 45 days of Nanoscope Therapeutics.

Source: Fundz verified event record.

Other recent leadership changes in Medical and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Arcutis names Robert Lisicki Executive Vice President, Chief Commercial Officer (November 5, 2026)
Grant C. Bogle Appointed as Class III Director at Immuneering Corporation (November 9, 2026)
OncoNano Medicine Appoints Brett P. Giroir as Chief Executive Officer (November 10, 2026)
Peter Anastasiou Appointed as President and CEO of Harmony Biosciences (October 30, 2026)
United Theranostics Appoints Amber Woodward-Smith as Chief Financial Officer (October 29, 2026)
Cognito Appoints Joe Perekupka as Chief Commercial Officer, Urvashi Tyagi as Chief Technology Officer, and Dave Watson as Chief Operating Officer (November 13, 2026)

Who to call at Nanoscope Therapeutics, and when

A new leader at Nanoscope Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Nanoscope Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Nanoscope Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nanoscope Therapeutics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nanoscope Therapeutics

Location

1312 BROWN TRAIL

Dallas, Texas, United States

About

Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nanoscope Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans